About Enumera Molecular
Enumera Molecular is a company based in Ann Arbor (United States) founded in 2022. Enumera Molecular has raised $31.05 million across 2 funding rounds from investors including Arboretum Ventures. Enumera Molecular offers products and services including EnumeraPlex. Enumera Molecular operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Ann Arbor, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.05 M (USD)
in 2 rounds
-
Latest Funding Round
$12.33 M (USD), Series B
Jul 16, 2026
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enumera Molecular
Enumera Molecular offers a comprehensive portfolio of products and services, including EnumeraPlex.
Platform for simplified, rapid molecular counting in clinical diagnostics and genomics.
Funding Insights of Enumera Molecular
Enumera Molecular has successfully raised a total of $31.05M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $12.33 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enumera Molecular
Enumera Molecular has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Arboretum Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Locked | Locked | Locked |
Investor details for Enumera Molecular
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enumera Molecular
Investment portfolio details for Enumera Molecular
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enumera Molecular
Detailed financials for Enumera Molecular
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enumera Molecular Comparisons
Peer comparison for Enumera Molecular
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enumera Molecular
Enumera Molecular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are developed.
|
Detailed competitors of Enumera Molecular
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enumera Molecular
Complete news archive for Enumera Molecular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enumera Molecular
Enumera Molecular was founded in 2022.
Enumera Molecular is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Matthew Cooper is the current CEO of Enumera Molecular.
Enumera Molecular is a funded company, having raised a total of $31.05M across 2 funding rounds to date.
Enumera Molecular was founded in 2022 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where liquid biopsy tools are manufactured to enable the assessment of biomolecules. Rapid and low-cost solutions are facilitated through these tools, supporting diagnostic applications in clinical and research settings. The companys efforts center on advancing non-invasive biomolecule analysis methods.
Enumera Molecular's top competitors include Guardant Health, Foundation Medicine and Natera.
Enumera Molecular offers EnumeraPlex.
Enumera Molecular has 1 investor. Key investors include Arboretum Ventures.